rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    OCUL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Our Small-Cap Biopharma Firm Presents

      Ocular Therapeutix detailed its outlook during the UBS Global Biopharma Conference in London.

      9h agoTheStreetOCUL
      Ocular Therapeutix at UBS Global Biopharma Conference 2026: filing nears
      Nov 17Investing.comOCULUBS
      Ocular: Maintaining 'Buy' On AXPAXLI NDA Submission Q4 2026 And DR Expansion Possibility
      Nov 13Seeking AlphaOCUL
      Ocular Therapeutix stock hits 52-week low at 6.0 USD
      Nov 13Investing.comOCUL
      Ocular Therapeutix (OCUL) On Phase 3 AMD Win And Why The Valuation Debate Persists

      What Ocular Therapeutix’s latest earnings reveal Ocular Therapeutix (OCUL) paired a high profile clinical milestone for AXPAXLI in wet AMD with fresh quarterly numbers. This gives a clearer picture of how the story looks on both science and cash flow. On the financial side, the firm reported Q3 2026 revenue of US$12.87 million, compared with US$14.54 million a year earlier, and a net loss of US$94.78 million, wider than the prior US$69.42 million loss. Over the first nine months of 2026,...

      Nov 12Yahoo FinanceAMDOCUL
      Ocular Therapeutix (OCUL) reports earnings tomorrow: what to expect

      Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) will be reporting results this Monday morning. Here’s what to look for.

      Nov 10Yahoo FinanceJAZZOCUL
      Ocular Therapeutix Inc (OCUL) Q3 2026 Earnings Call Highlights: Landmark Phase 3 Wins, NDA on ...

      Ocular Therapeutix Inc (OCUL) is poised to file its AXPAXLI NDA in wet AMD in Q4 2026 on the strength of SOL-1 superiority data, backed by a $530.6 million cash position funding operations into 2028.

      Nov 10Yahoo FinanceOCUL
      Ocular Therapeutix, Inc. Q3 2026 Earnings Call Summary
      Nov 9Yahoo FinanceOCUL
      What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings Call
      Nov 9Yahoo FinanceOCUL
      Why is Ocular Therapeutix stock sliding today?
      Nov 9Investing.comOCUL
      Ocular Therapeutix falls on third quarter earnings miss
      Nov 9Investing.comOCUL
      New Ocular Therapeutix Price Target After Positive FDA Update

      We’re taking a close look after earnings.

      Nov 9TheStreetOCUL
      Ocular Therapeutix Q3 2026 Earnings Call Transcript
      Nov 9BenzingaOCUL
      Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
      Nov 9Yahoo FinanceOCUL
      Ocular Therapeutix (NASDAQ:OCUL) reports sales below analyst estimates in Q3 2026 earnings, stock drops
      Nov 9Yahoo FinanceOCUL
      Ocular Therapeutix earnings up next as AXPAXLI filing nears
      Nov 9Investing.comOCUL
      Is Ocular Therapeutix (OCUL) Overvalued Given Its Current Sales Base?
      Nov 6Yahoo FinanceOCUL
      I’m Eying Ocular Therapeutix, Rocket Lab; Also Small Caps Steady

      Here are my two planned trades for today and why small caps aren’t so bad off.

      Nov 2TheStreetOCULRKLB
      Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

      BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in November 2026. Upcoming Investor Conference: UBS Global Biopharma Conference 2026: Date: Tuesday, November 17, 2026Fireside Chat: 12:00 – 12:30 PM GMTPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLoca

      Oct 29Yahoo FinanceOCUL
      Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity

      Ocular Therapeutix's AXPAXLI's strong Phase 3 SOL-1 results support a clear regulatory path, with NDA filing expected in Q4. See why I rate OCUL stock a Buy.

      Oct 25Seeking AlphaOCUL
      Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Palvella Therapeutics (PVLA)

      Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.

      Oct 21The Globe and MailOCULPVLA
      Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win
      Oct 20Yahoo FinanceOCUL
      Ocular Therapeutix Has 75% Success Probability for Axpaxli in Wet Age-Related Macular Degeneration, UBS Says
      Oct 20Yahoo FinanceOCUL
      Ocular Therapeutix at chardan healthcare conference: wet amd push advances
      Oct 20Investing.comAMDOCUL
      H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy
      Oct 20Investing.comOCUL
      Ocular Therapeutix stock hits 52-week low at 6.23 USD
      Oct 19Investing.comOCUL
      Ocular Therapeutix Chief Strategy Officer Resigns for New Role

      Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.

      Oct 17The Globe and MailOCUL
      Novavax, Ocular Therapeutix, and QuidelOrtho Shares Plummet, What You Need To Know
      Oct 16Yahoo FinanceNVAXOCULQDEL
      Ocular Therapeutix, Inc. (OCUL) Presents at American Academy of Ophthalmology Retina Subspeciality Day - Slideshow (NASDAQ:OCUL) 2026-10-15
      Oct 15Seeking AlphaOCUL
      1 Russell 2000 Stock with Solid Fundamentals and 2 We Avoid

      Detailed price information for Excelerate Energy Inc Cl A (EE-N) from The Globe and Mail including charting and trades.

      Oct 15The Globe and MailOCUL
      Ocular Therapeutix CLO Todd Anderman sells $87,363 in company stock
      Oct 14Investing.comOCUL
      Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)

      Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailOCUL
      UBS Initiates Coverage on Ocular Therapeutix With Buy Rating, $14 Price Target
      Oct 12Yahoo FinanceOCUL
      UBS initiates Ocular Therapeutix stock with buy rating on Axpaxli potential
      Oct 12Investing.comOCUL
      Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BEDFORD, Mass., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to fifteen newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq List

      Oct 9Yahoo FinanceOCUL
      Ocular Therapeutix, Inc. (OCUL) Presents at Euretina 2026 - Slideshow (NASDAQ:OCUL) 2026-10-06

      2026-10-06. The following slide deck was published by Ocular Therapeutix, Inc.

      Oct 6Seeking AlphaOCUL
      Ocular Therapeutix CDO Peter Kaiser sells $70,429 in stock
      Oct 6Investing.comOCUL
      Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter - Align Technology (NASDAQ:ALGN)

      Oversold health care stocks Align Technology, Dianthus Therapeutics and Ocular Therapeutix show RSI readings near or below 30, signaling potential value.

      Oct 6BenzingaALGNDNTHOCUL
      Ocular Therapeutix (OCUL) Stock Still Looks Pricey As 145% Gain Draws Scrutiny
      Oct 2Yahoo FinanceOCUL
      OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD

      OCUL stock selloff began on Monday after Kodiak Sciences and 4D Molecular posted updates from clinical trials of their eye-disease drugs.

      Oct 1Yahoo FinanceOCUL
      Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

      BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026. Upcoming Investor Conference: Chardan 10th Annual Healthcare Conference:Date: Tuesday, October 20, 2026Fireside Chat: 9:45 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Ne

      Oct 1Yahoo FinanceOCUL
      Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Ocular Therapeutix (OCUL) and Regeneron (REGN)

      Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

      Sep 30The Globe and MailOCULSMMT
      RBC Capital reiterates Ocular Therapeutix stock rating on wAMD treatment potential
      Sep 29Investing.comOCUL
      Some Good News After a Harsh Selloff for Our Small-Cap Pharma Name

      We’re buying more shares after a harsh day for the position.

      Sep 29TheStreetOCUL
      OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
      Sep 28Yahoo FinanceOCUL
      Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know

      A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.

      Sep 23Yahoo FinanceANIPOCUL
      Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
      Sep 23Yahoo FinanceOCUL
      New Ocular Therapeutix Target Price Amid Support

      The small-cap firm is likely to see defense by professional managers.

      Sep 18TheStreetOCUL
      Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Sep 18Yahoo FinanceOCUL
      H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy
      Sep 16Investing.comOCUL

      This is the newest page. Registered accounts read further back.